The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Is clopidogrel as the P2Y12 inhibitor a wise choice for long-term monotherapy in patients undergoing stenting?

EuroIntervention 2021;17:e865-e866. DOI: 10.4244/EIJV17I11A144

1. Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, MD, USA
International practice guidelines uniformly recommend dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor in patients undergoing drug-eluting stent (DES) implantation to reduce ischaemic events such as stent thrombosis. In high-risk coronary artery disease (CAD) patients, potent platelet P2Y12 inhibitors such as prasugrel or ticagrelor are preferred whereas in stable CAD patients clopidogrel is widely used1,2. A shorter duration of DAPT (1-3 months) followed by mono antiplatelet therapy has been suggested based on the significantly lower incidences of stent thrombosis with second-generation DES1,2. A recent meta-analysis suggested that de-escalation of DAPT after 1-3 months to monotherapy ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
High bleeding risk – the clinical context matters